The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…
WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules.WuXia293Stable platform maintains…
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by…
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…